Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights-Reference-Cited by-同舟云学术

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights

Published:2024-08 Issue:8 Volume:20 Page:1035-1039
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncol Pract

Author:

Rose Michal G.¹^ORCID,Kennedy Erin B.²^ORCID,Abou-Alfa Ghassan K.³⁴⁵^ORCID,Finn Richard S.⁶^ORCID,Gade Terence⁷^ORCID,Kelley R. Kate⁸^ORCID,Taddei Tamar¹^ORCID,Gordan John D.⁸^ORCID

Affiliation:

1. Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, CT

2. American Society of Clinical Oncology, Alexandria, VA

3. Memorial Sloan Kettering Cancer Center, New York, NY

4. Weill Medical College at Cornell University, New York, NY

5. Trinity College Dublin Medical School, Dublin, Ireland

6. Geffen School of Medicine, UCLA, Los Angeles, CA

7. Penn Medicine, Philadelphia, PA

8. University of California, San Francisco, San Francisco, CA

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.24.00189

Reference17 articles.

1. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

2. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

3. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

4. SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

5. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma;Investigational New Drugs;2024-08-30